Application of multitarget stool FIT-DNA test for cancer screening in colorectal cancer patients and their spouses and first-degree relatives

doi:10.3877/cma.j.issn.2095-3224.2021.03.003

Abstract

Abstract:

Objective

To assess the clinical performance of Multitarget stool FIT-DNA test for colorectal cancer (CRC) screening, and investigate the risk factors of developing colorectal cancer and precancerous lesions in spouses and first-degree relatives of CRC patients.

Methods

CRC patients and their spouses and first-degree relatives were recruited from colorectal surgery or general surgery departments of eight hospitals in China between April 2017 to March 2019. Multitarget stool FIT-DNA test results were compared with colonoscopy outcomes.

Results

Of 211 valid participants, 135 (64.0%) were colorectal cancer patients, 47 (22.3% )were spouses and 29 (13.7%) were first-degree relatives. Colonoscopy revealed 14.9% (7/47) of spouses and 24.1% (7/29) of first-degree relatives had colonoscopic lesions. The sensitivity and specificity of Multitarget stool FIT-DNA test were 89.6% (121/135) and 96.8% (60/62) respectively.

Conclusion

The study confirmed the clinical performance of Multitarget stool FIT-DNA test in CRC screening, and provided essential data for large scale prospective study in the next stage.

Key words: Colorectal neoplasms, Multitarget stool FIT-DNA test, Screening, Spouse, First degree relatives

Xu Guan, Chenxi Ma, Wei Wang, Dexiang Zhu, Aobo Zhuang, Ruogu Wang, Chuangqi Chen, Jiaying Li, Haiping Pei, Shaozhong Wei, Jianmin Xu, Xuejun Sun, Xishan Wang. Application of multitarget stool FIT-DNA test for cancer screening in colorectal cancer patients and their spouses and first-degree relatives[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2021, 10(03): 237-242.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2021.03.003

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2021/V10/I03/237

Figures/Tables 4

References 13

1	Chen W, Zheng R, Baade P, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
2	中国抗癌协会大肠癌专业委员会中国结直肠肿瘤早诊筛查策略制订专家组. 中国结直肠肿瘤早诊筛查策略专家共识[J]. 中华胃肠外科杂志, 2018, 21(10): 1081-1086.
3	Butterworth A, Higgins J, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: A meta-analysis[J]. Eur J Cancer, 2006, 42(2): 216-227.
4	Lew J, St John D, Xu X, et al. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study[J]. Lancet Public Health, 2017, 2(7): e331-e340.
5	Tanday S. Updated Canadian colorectal cancer screening guidelines[J]. Lancet Oncol, 2016, 17(4): e137.
6	Smith R, Andrews K, Brooks D, et al. Cancer screening in the United States, 2017:A review of current American Cancer Society guidelines and current issues in cancer screening[J]. CA Cancer J Clin, 2017, 67(2): 100-121.
7	Imperiale T, Ransohoff D, Itzkowitz S, et al. Multitarget stool DNA testing for colorectal-cancer screening[J]. N Engl J Med, 2014, 370(14): 1287-1297.
8	Ridge J, Statz S. Exact Sciences' experience with the FDA and CMS parallel review program[J]. Expert Rev Mol Diagn, 2015, 15(9): 1117-1124.
9	马志刚, 朱晓麟, 马丽红, 等. 基于多靶点粪便FIT-DNA 联合检测技术的结直肠癌早期筛查结果分析[J/CD]. 中华结直肠疾病电子杂志, 2019, 8(6): 616-621.
10	Jiayi M, Yangqin H, Shanrong C, et al. Plausibility of an extensive use of stool DNA test for screening advanced colorectal neoplasia[J]. Clin Chim Acta, 2020, 501: 42-47.
11	钟英强, 邹勇男, 李海刚, 等. 大肠癌患者一级亲属的电子肠镜与粪便潜血试验的筛查结果分析[J]. 中华消化内镜杂志, 2006, 23(5): 340-343.
12	Johns L, Houlston R. A systematic review and meta-analysis of familial colorectal cancer risk[J]. Am J Gastroenterol, 2001, 96(10): 2992-3003.
13	Tabung F, Liu L, Wang Wet al. Association of Dietary Inflammatory Potential With Colorectal Cancer Risk in Men and Women[J]. JAMA Oncol, 2018, 5(4):579.

	入组例数	FIT-DNA检测
	入组例数	阳性例数	%
总计	211	127	60.2
入组人群
患者本人	135	121	89.6
患者配偶	47	4	8.5
患者一级亲属	29	2	6.9
年龄（岁）
＜40	13	2	15.4
40~49	18	3	16.7
50~59	62	34	54.8
60~69	83	58	69.9
≥70	35	30	85.7
性别
男	130	83	63.8
女	81	44	54.3

	入组例数	FIT-DNA检测
	入组例数	阳性例数	%
总计	211	127	60.2
入组人群
患者本人	135	121	89.6
患者配偶	47	4	8.5
患者一级亲属	29	2	6.9
年龄（岁）
＜40	13	2	15.4
40~49	18	3	16.7
50~59	62	34	54.8
60~69	83	58	69.9
≥70	35	30	85.7
性别
男	130	83	63.8
女	81	44	54.3

	患者例数	FIT-DNA检测		χ²值	P值
	患者例数	阳性例数	%	χ²值	P值
总计	135	121	89.6
年龄（岁）				0.013	0.910
＜40	2	2	100.0
40~49	4	3	75.0
50~59	34	32	94.1
60~69	63	54	85.7
≥70	32	30	93.8
性别				3.032	0.082
男	93	80	86.0
女	42	41	97.6
病灶位置				0.413	0.521
左半结肠	100	89	89.0
右半结肠	29	26	89.7
位置不详	6	6	100.0
分化程度				0.157	0.692
低分化	38	35	92.1
中高分化	86	76	88.4
分化不详	11	10	90.9
分期				0.336	0.562
Ⅰ期	25	22	88.0
Ⅱ期	54	49	90.7
Ⅲ期	29	25	86.2
Ⅳ期	13	11	84.6
分期不详	14	14	100.0

	患者例数	FIT-DNA检测		χ²值	P值
	患者例数	阳性例数	%	χ²值	P值
总计	135	121	89.6
年龄（岁）				0.013	0.910
＜40	2	2	100.0
40~49	4	3	75.0
50~59	34	32	94.1
60~69	63	54	85.7
≥70	32	30	93.8
性别				3.032	0.082
男	93	80	86.0
女	42	41	97.6
病灶位置				0.413	0.521
左半结肠	100	89	89.0
右半结肠	29	26	89.7
位置不详	6	6	100.0
分化程度				0.157	0.692
低分化	38	35	92.1
中高分化	86	76	88.4
分化不详	11	10	90.9
分期				0.336	0.562
Ⅰ期	25	22	88.0
Ⅱ期	54	49	90.7
Ⅲ期	29	25	86.2
Ⅳ期	13	11	84.6
分期不详	14	14	100.0

	家属例数	FIT-DNA检测		χ²值	P值
	家属例数	阳性例数	%	χ²值	P值
总计	76	6	7.9
入组人群				0.063	0.801
患者配偶	47	4	8.5
患者一级亲属	29	2	6.9
年龄（岁）				3.510	0.061
＜40	11	0	0
40~49	14	0	0
50~59	28	2	7.1
60~69	20	4	20.0
≥70	3	0	0
性别				0.004	0.947
男	37	3	8.1
女	39	3	7.7
肠镜结果				6.905	0.009
正常	62	2	3.2
异常	14	4	28.6
肠镜异常结果				3.881	0.144
腺瘤	3	1	33.3
息肉	8	1	12.5
炎症	3	2	66.7

Please choose a citation manager

Content to export